Innovation Potential: If bel-sar achieves approval and enters the market, this could lead to significant upside.
Clinical Progress: The company is now in Phase 3 for one of its key indications, which is progress for a small biotech company.
Aura Biosciences
+1
Financial Liquidity: As of Q2 2025, Aura reports cash, equivalents, and liquid investments of approximately $177.3 million, after raising through a capital offering.
Nasdaq
Analyst Rating: According to StockAnalysis, the average target price is ~$22.29 per share (~+260% potential from the current price of ~$6.16 as of October 2025)
StockAnalysis
Clinical Progress: The company is now in Phase 3 for one of its key indications, which is progress for a small biotech company.
Aura Biosciences
+1
Financial Liquidity: As of Q2 2025, Aura reports cash, equivalents, and liquid investments of approximately $177.3 million, after raising through a capital offering.
Nasdaq
Analyst Rating: According to StockAnalysis, the average target price is ~$22.29 per share (~+260% potential from the current price of ~$6.16 as of October 2025)
StockAnalysis
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.